腺嘌呤 A（2A）受体拮抗剂与帕金森病。
Adenosine A(2A) Receptor Antagonists and Parkinson's Disease.
机构信息
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. , Welsh and McKean Roads, P.O. Box 776, Spring House, Pennsylvania 19477, United States.
出版信息
ACS Chem Neurosci. 2011 Oct 19;2(10):555-67. doi: 10.1021/cn2000537. Epub 2011 Jun 21.
Abstract
This Review summarizes and updates the work on adenosine A(2A) receptor antagonists for Parkinson's disease from 2006 to the present. There have been numerous publications, patent applications, and press releases within this time frame that highlight new medicinal chemistry approaches to this attractive and promising target to treat Parkinson's disease. The Review is broken down by scaffold type and will discuss the efforts to optimize particular scaffolds for activity, pharmacokinetics, and other drug discovery parameters. The majority of approaches focus on preparing selective A(2A) antagonists, but a few approaches to dual A(2A)/A(1) antagonists will also be highlighted. The in vivo profiles of compounds will be highlighted and discussed to compare activities across different chemical series. A clinical report and update will be given on compounds that have entered clinical trials.
摘要
这篇综述总结和更新了 2006 年至今有关腺苷 A（2A）受体拮抗剂治疗帕金森病的研究进展。在此期间，有大量出版物、专利申请和新闻稿强调了针对这一有吸引力和有前景的治疗帕金森病靶点的新型药物化学方法。综述按支架类型进行了划分，并将讨论针对特定支架的活性、药代动力学和其他药物发现参数进行优化的努力。大多数方法都集中在制备选择性 A（2A）拮抗剂上，但也将重点介绍一些双重 A（2A）/A（1）拮抗剂的方法。将突出并讨论化合物的体内概况，以比较不同化学系列的活性。将提供已进入临床试验的化合物的临床报告和更新。
相似文献
1
Adenosine A(2A) Receptor Antagonists and Parkinson's Disease.腺嘌呤 A（2A）受体拮抗剂与帕金森病。
ACS Chem Neurosci. 2011 Oct 19;2(10):555-67. doi: 10.1021/cn2000537. Epub 2011 Jun 21.
2
The adenosine A(2A) antagonistic properties of selected C8-substituted xanthines.某些C8取代黄嘌呤的腺苷A(2A)拮抗特性。
Bioorg Chem. 2013 Aug;49:49-58. doi: 10.1016/j.bioorg.2013.06.006. Epub 2013 Jul 4.
3
Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A AR ligands with in vivo efficacy against animal model of Parkinson's disease.1,3,7,8-四取代黄嘌呤类化合物的合成、生物评价及分子模拟研究作为高效和选择性的 A AR 配体，对帕金森病动物模型具有体内疗效。
Bioorg Chem. 2019 Jun;87:601-612. doi: 10.1016/j.bioorg.2019.03.032. Epub 2019 Mar 19.
4
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.在帕金森病动物模型中对一种双重腺苷 A2A/A1 受体拮抗剂的体内特征进行鉴定。
J Med Chem. 2010 Nov 25;53(22):8104-15. doi: 10.1021/jm100971t. Epub 2010 Oct 25.
5
A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?A2A 腺苷受体拮抗剂作为治疗候选药物：它们仍然是一个有趣的挑战吗？
Mini Rev Med Chem. 2018;18(14):1168-1174. doi: 10.2174/1389557518666180423113051.
6
Recent developments in the field of A2A and A3 adenosine receptor antagonists.
Eur J Med Chem. 2003 Apr;38(4):367-82. doi: 10.1016/s0223-5234(03)00042-4.
7
8
Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A and A receptor antagonists.1,3 - 二乙基 - 7 - 甲基 - 8 -（苯氧甲基）黄嘌呤衍生物作为新型腺苷A和A受体拮抗剂的发现
Bioorg Med Chem Lett. 2016 Dec 15;26(24):5951-5955. doi: 10.1016/j.bmcl.2016.10.086. Epub 2016 Oct 31.
9
Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones.强效和选择性的腺苷 A(2A)受体拮抗剂：[1,2,4]-三唑并[4,3-c]嘧啶-3-酮。
Bioorg Med Chem Lett. 2011 Apr 15;21(8):2497-501. doi: 10.1016/j.bmcl.2011.02.045. Epub 2011 Feb 24.
10
8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists.8-取代的2-炔基-N(9)-炔丙基腺嘌呤作为A2A腺苷受体拮抗剂
Bioorg Med Chem. 2014 Jun 15;22(12):3072-82. doi: 10.1016/j.bmc.2014.04.041. Epub 2014 Apr 28.
引用本文的文献
1
Metabolomics Unveils Disrupted Pathways in Parkinson's Disease: Toward Biomarker-Based Diagnosis.代谢组学揭示帕金森病中的紊乱途径：迈向基于生物标志物的诊断。
ACS Chem Neurosci. 2024 Sep 4;15(17):3168-3180. doi: 10.1021/acschemneuro.4c00355. Epub 2024 Aug 23.
2
Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?阿尔茨海默病和帕金森病的药物研发：我们如今何去何从？
Pharmaceutics. 2024 May 24;16(6):708. doi: 10.3390/pharmaceutics16060708.
3
The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson's Disease.泛素蛋白酶体系统作为帕金森病的治疗领域。
Neuromolecular Med. 2023 Sep;25(3):313-329. doi: 10.1007/s12017-023-08738-1. Epub 2023 Feb 5.
4
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.左旋多巴诱导的帕金森病运动障碍：发病机制与新兴治疗策略。
Cells. 2022 Nov 23;11(23):3736. doi: 10.3390/cells11233736.
5
Marine Natural Products from the Russian Pacific as Sources of Drugs for Neurodegenerative Diseases.俄罗斯太平洋海域的海洋天然产物可作为神经退行性疾病药物的来源。
Mar Drugs. 2022 Nov 11;20(11):708. doi: 10.3390/md20110708.
6
P2X7 Receptor and Purinergic Signaling: Orchestrating Mitochondrial Dysfunction in Neurodegenerative Diseases.P2X7 受体和嘌呤能信号：在神经退行性疾病中协调线粒体功能障碍。
eNeuro. 2022 Nov 14;9(6). doi: 10.1523/ENEURO.0092-22.2022. Print 2022 Nov-Dec.
7
Histone Deacetylases as Epigenetic Targets for Treating Parkinson's Disease.组蛋白去乙酰化酶作为治疗帕金森病的表观遗传学靶点
Brain Sci. 2022 May 21;12(5):672. doi: 10.3390/brainsci12050672.
8
The Pharmacological Potential of Adenosine A Receptor Antagonists for Treating Parkinson's Disease.腺苷 A 受体拮抗剂治疗帕金森病的药理学潜力。
Molecules. 2022 Apr 6;27(7):2366. doi: 10.3390/molecules27072366.
9
Discovery of Pyridone-Substituted Triazolopyrimidine Dual A/A AR Antagonists for the Treatment of Ischemic Stroke.用于治疗缺血性中风的吡啶酮取代的三唑并嘧啶双 A/A AR 拮抗剂的发现。
ACS Med Chem Lett. 2022 Feb 21;13(3):436-442. doi: 10.1021/acsmedchemlett.1c00599. eCollection 2022 Mar 10.
10
Neurochemical and Behavioral Consequences of Ethanol and/or Caffeine Exposure: Effects in Zebrafish and Rodents.乙醇和/或咖啡因暴露的神经化学和行为后果：斑马鱼和啮齿动物的影响。
Curr Neuropharmacol. 2022 Mar 4;20(3):560-578. doi: 10.2174/1570159X19666211111142027.
本文引用的文献
1
Substituted thieno[2,3-d]pyrimidines as adenosine A2A receptor antagonists.取代的噻吩并[2,3-d]嘧啶作为腺苷 A2A 受体拮抗剂。
Bioorg Med Chem Lett. 2013 May 1;23(9):2688-91. doi: 10.1016/j.bmcl.2013.02.078. Epub 2013 Feb 27.
2
Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones.强效和选择性的腺苷 A(2A)受体拮抗剂：[1,2,4]-三唑并[4,3-c]嘧啶-3-酮。
Bioorg Med Chem Lett. 2011 Apr 15;21(8):2497-501. doi: 10.1016/j.bmcl.2011.02.045. Epub 2011 Feb 24.
3
Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.新型帕金森病疗法：腺苷 A（2A）受体拮抗剂。
Expert Opin Drug Metab Toxicol. 2011 Apr;7(4):441-55. doi: 10.1517/17425255.2011.557066. Epub 2011 Feb 19.
4
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.在帕金森病动物模型中对一种双重腺苷 A2A/A1 受体拮抗剂的体内特征进行鉴定。
J Med Chem. 2010 Nov 25;53(22):8104-15. doi: 10.1021/jm100971t. Epub 2010 Oct 25.
5
Discovery of 2-aminoimidazopyridine adenosine A(2A) receptor antagonists.发现 2-氨基咪唑并吡啶腺苷 A(2A)受体拮抗剂。
Bioorg Med Chem Lett. 2010 Nov 15;20(22):6845-9. doi: 10.1016/j.bmcl.2010.08.064. Epub 2010 Aug 19.
6
Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists.以乙基 2-氨基-4-苯基噻唑-5-羧酸酯系列羧酰胺为先导化合物的优化研究新型腺嘌呤 A2A 受体拮抗剂。
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5241-4. doi: 10.1016/j.bmcl.2010.06.138. Epub 2010 Jul 24.
7
Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease.用于治疗帕金森病的腺苷A(2A)受体拮抗剂的最新发现进展。
Curr Opin Drug Discov Devel. 2010 Jul;13(4):466-80.
8
Synthetic studies on selective adenosine A2A receptor antagonists. Part II: synthesis and structure-activity relationships of novel benzofuran derivatives.选择性腺苷 A2A 受体拮抗剂的合成研究。第二部分：新型苯并呋喃衍生物的合成及构效关系。
Bioorg Med Chem Lett. 2010 Jun 15;20(12):3768-71. doi: 10.1016/j.bmcl.2010.04.058. Epub 2010 Apr 18.
9
Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.亚甲基胺取代的芳基并嘧啶作为有效的腺苷 A(2A)/A(1)拮抗剂。
Bioorg Med Chem Lett. 2010 May 1;20(9):2864-7. doi: 10.1016/j.bmcl.2010.03.042. Epub 2010 Mar 11.
10
Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.优化芳基吲唑嘧啶类化合物作为强效的腺苷 A2A/A1 拮抗剂。
Bioorg Med Chem Lett. 2010 May 1;20(9):2868-71. doi: 10.1016/j.bmcl.2010.03.024. Epub 2010 Mar 7.
Zotero 插件